EA201891744A1 - ГЛЮКОНО-δ-ЛАКТОН ДЛЯ ЛЕЧЕНИЯ ВАГИНАЛЬНЫХ ГРИБКОВЫХ ИНФЕКЦИЙ - Google Patents

ГЛЮКОНО-δ-ЛАКТОН ДЛЯ ЛЕЧЕНИЯ ВАГИНАЛЬНЫХ ГРИБКОВЫХ ИНФЕКЦИЙ

Info

Publication number
EA201891744A1
EA201891744A1 EA201891744A EA201891744A EA201891744A1 EA 201891744 A1 EA201891744 A1 EA 201891744A1 EA 201891744 A EA201891744 A EA 201891744A EA 201891744 A EA201891744 A EA 201891744A EA 201891744 A1 EA201891744 A1 EA 201891744A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glucono
lacton
treatment
fungal infections
lactone
Prior art date
Application number
EA201891744A
Other languages
English (en)
Other versions
EA036748B1 (ru
Inventor
Ульф Эллервик
Олов Стернер
Хелена Стревенс
Софи Маннер
Original Assignee
Гедеа Биотек Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гедеа Биотек Аб filed Critical Гедеа Биотек Аб
Publication of EA201891744A1 publication Critical patent/EA201891744A1/ru
Publication of EA036748B1 publication Critical patent/EA036748B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/06—Crucible or pot furnaces heated electrically, e.g. induction crucible furnaces with or without any other source of heat
    • F27B14/061—Induction furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/08—Details peculiar to crucible or pot furnaces
    • F27B14/10—Crucibles
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B3/00—Hearth-type furnaces, e.g. of reverberatory type; Tank furnaces
    • F27B3/10—Details, accessories, or equipment peculiar to hearth-type furnaces
    • F27B3/12—Working chambers or casings; Supports therefor
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D1/00—Casings; Linings; Walls; Roofs
    • F27D1/16—Making or repairing linings increasing the durability of linings or breaking away linings
    • F27D1/1626—Making linings by compacting a refractory mass in the space defined by a backing mould or pattern and the furnace wall
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/22—Furnaces without an endless core
    • H05B6/24—Crucible furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/06—Crucible or pot furnaces heated electrically, e.g. induction crucible furnaces with or without any other source of heat
    • F27B14/061—Induction furnaces
    • F27B2014/066—Construction of the induction furnace
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27B—FURNACES, KILNS, OVENS, OR RETORTS IN GENERAL; OPEN SINTERING OR LIKE APPARATUS
    • F27B14/00—Crucible or pot furnaces
    • F27B14/08—Details peculiar to crucible or pot furnaces
    • F27B2014/0837—Cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к фармацевтической готовой форме для введения во влагалище, при этом готовая форма содержит фармацевтически приемлемое вспомогательное средство и глюконо-δ-лактон, при этом глюконо-δ-лактон присутствует в количестве, составляющем 5-99 мас.% готовой формы. Изобретение также относится к фармацевтической готовой форме согласно изобретению для применения при предотвращении или лечении урогенитальной грибковой инфекции. Кроме того, изобретение относится к глюконо-δ-лактону (формула (III)) для применения при предотвращении или лечении грибковой инфекции.
EA201891744A 2016-04-06 2017-04-06 Глюконо--лактон для лечения вагинальных грибковых инфекций EA036748B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650467 2016-04-06
PCT/EP2017/058268 WO2017174731A1 (en) 2016-04-06 2017-04-06 Glucono delta-lactone for treatment of vaginal fungal infections

Publications (2)

Publication Number Publication Date
EA201891744A1 true EA201891744A1 (ru) 2019-03-29
EA036748B1 EA036748B1 (ru) 2020-12-16

Family

ID=58530540

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891744A EA036748B1 (ru) 2016-04-06 2017-04-06 Глюконо--лактон для лечения вагинальных грибковых инфекций

Country Status (22)

Country Link
US (2) US10993907B2 (ru)
EP (1) EP3439633B1 (ru)
JP (1) JP6967785B2 (ru)
KR (1) KR102346658B1 (ru)
CN (1) CN109069413B (ru)
AU (1) AU2017248050B2 (ru)
BR (1) BR112018070370A2 (ru)
CA (1) CA3013809C (ru)
CL (1) CL2018002705A1 (ru)
DK (1) DK3439633T3 (ru)
EA (1) EA036748B1 (ru)
ES (1) ES2896680T3 (ru)
HU (1) HUE056303T2 (ru)
IL (1) IL261796B (ru)
MX (1) MX2018012210A (ru)
MY (1) MY198473A (ru)
PH (1) PH12018502131A1 (ru)
PL (1) PL3439633T3 (ru)
SG (1) SG11201807475VA (ru)
UA (1) UA123954C2 (ru)
WO (1) WO2017174731A1 (ru)
ZA (1) ZA201804938B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102650182B1 (ko) * 2017-10-06 2024-03-21 게데아 바이오테크 아베 미생물 감염의 치료 및/또는 예방에서 사용하기 위한 글루콘산 유도체
PE20220381A1 (es) 2019-04-05 2022-03-18 Gedea Biotech Ab Formulacion de tableta vaginal

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5942250A (en) * 1986-12-23 1999-08-24 Tristrata Technology, Inc. Compositions and methods for enhancing the topical effects of sunscreen agents
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
CN1051454C (zh) 1994-12-13 2000-04-19 周彦华 含有葡萄糖酸δ-内酯的阴道避孕药
AU9023198A (en) 1998-06-25 2000-01-10 Theratech, Inc. Incorporation of latent acid solubilizing agents in coated pellet formulations to obtain ph independent release
AT407111B (de) * 1998-12-22 2000-12-27 Gergely Dr & Co Zucker- und/oder zuckeralkoholhältiges matrixmaterial und verfahren zu seiner herstellung
AUPP839499A0 (en) 1999-01-29 1999-02-25 Australian National University, The A method for controlling plant pathogens, and agents useful for same
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20060172007A1 (en) * 2001-05-01 2006-08-03 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
EP2387882A3 (en) 2002-08-12 2012-10-31 Lonza Inc. Antimicrobial compositions comprising cinnamaldehyde
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
US20070059278A1 (en) 2005-09-12 2007-03-15 Nawaz Ahmad Anhydrous composition containing an acid-acid buffer system
WO2008071783A1 (en) 2006-12-15 2008-06-19 Ellen Ab Absorbent article comprising lactic acid producing bacteria
JP5409596B2 (ja) 2007-03-30 2014-02-05 ラキュアー エービー 婦人科の障害の治療における乳酸オリゴマーの使用
JP5345937B2 (ja) 2007-09-05 2013-11-20 株式会社ポーラファルマ 抗真菌組成物
US20170173056A1 (en) 2014-03-20 2017-06-22 Cheryl Lee Eberting Compositions for the treatment of dermatological diseases and disorders

Also Published As

Publication number Publication date
HUE056303T2 (hu) 2022-02-28
ZA201804938B (en) 2022-03-30
MY198473A (en) 2023-08-31
US20190110983A1 (en) 2019-04-18
KR102346658B1 (ko) 2022-01-03
US11696891B2 (en) 2023-07-11
ES2896680T3 (es) 2022-02-25
PL3439633T3 (pl) 2022-01-10
US10993907B2 (en) 2021-05-04
CA3013809C (en) 2024-01-02
JP2019510761A (ja) 2019-04-18
DK3439633T3 (da) 2021-12-20
IL261796A (en) 2018-10-31
BR112018070370A2 (pt) 2019-01-29
EP3439633B1 (en) 2021-09-15
SG11201807475VA (en) 2018-10-30
MX2018012210A (es) 2018-12-17
IL261796B (en) 2021-06-30
CA3013809A1 (en) 2017-10-12
WO2017174731A1 (en) 2017-10-12
UA123954C2 (uk) 2021-06-30
AU2017248050B2 (en) 2022-05-26
CN109069413A (zh) 2018-12-21
JP6967785B2 (ja) 2021-11-17
EA036748B1 (ru) 2020-12-16
KR20180127314A (ko) 2018-11-28
US20210212937A1 (en) 2021-07-15
CN109069413B (zh) 2022-09-27
CL2018002705A1 (es) 2018-11-30
AU2017248050A1 (en) 2018-11-08
PH12018502131A1 (en) 2019-09-16
EP3439633A1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
MY192607A (en) Antiviral beta-amino acid ester phosphodiamide compounds
NZ751197A (en) Compounds and methods of treating infections
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201390198A1 (ru) Гетероциклическое соединение
NZ607580A (en) N-heteroaryl compounds
EA201591027A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201791019A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
NZ764310A (en) Antibacterial compounds
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
EA201891744A1 (ru) ГЛЮКОНО-δ-ЛАКТОН ДЛЯ ЛЕЧЕНИЯ ВАГИНАЛЬНЫХ ГРИБКОВЫХ ИНФЕКЦИЙ
MX2019007213A (es) Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina.
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
EA201491982A1 (ru) Антибактериальные хинолиновые производные
EA201992448A1 (ru) Лечение бактериальной вагинальной инфекции
NZ708526A (en) Novel rock inhibitors
WO2022023533A3 (en) Antiviral use of liraglutide and gefitinib
EA201491992A1 (ru) Новые соединения и новое применение
EA201491971A1 (ru) Антибактериальные хинолиновые производные
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection